Andere Sprachen Kancera AB

Aktien

A2QQQ4

SE0015658570

KAN

Markt geschlossen - Nasdaq Stockholm Andere Börsenplätze 17:29:30 06.05.2024			% 5 Tage	% 1. Jan.
1,45 ^SEK	-4,73 %		+3,13 %	-68,10 %

03.05.	Kancera AB (publ) meldet positive Ergebnisse der klinischen Phase I-Studie mit KAND145 bei gesunden Probanden	CI
23.02.	Kancera AB (publ) berichtet über die Ergebnisse für das am 31. Dezember 2023 endende Geschäftsjahr	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Kancera meets the primary objectives of the KAND145 clinical phase I study	03.05.
Kancera AB Reports Positive Results from the Clinical Phase I Study with KAND145 in Healthy Subjects	03.05.
Kancera announces the outcome of the company's rights issue	20.03.
Kancera publishes prospectus in connection with the company’s rights issue	01.03.
Kancera resolves on a rights issue of approximately SEK 121.9 million	23.02.
Interim Report Fourth Quarter 2023, October 1 – December 31 Kancera AB (publ.), org.no. 556806-8851	23.02.
Kancera signs license agreement and obtains global commercial rights to the results from the FRACTAL study	23.02.
Kancera AB Reports Earnings Results for the Full Year Ended December 31, 2023	23.02.
Kancera AB Signs A License Agreement with the University of Newcastle	23.02.
Kancera AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	23.02.
Kancera presents the statistical analysis of top line data from the FRACTAL study	06.02.
Kancera AB Presents the statistical Analysis of Top Line Data from the FRACTAL Study	06.02.
Kancera reports positive top line results from the FRACTAL study	20.12.
Kancera AB Reports Positive Top Line Results from the FRACTAL Study	20.12.
Kancera provides operational update in connection with release of financial interim report for third quarter 2023	17.11.
Interim Report Third Quarter July 1 – September 30, 2023 Kancera AB (publ.), org.no. 556806-8851	17.11.
Kancera AB Provides Operational Update Regarding Fractalkine Block Blockers KAN567 and KAND145	17.11.
Kancera AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	17.11.
Kancera reports that the phase I study of KAND145 has received regulatory approval	23.10.23
Kancera AB Receives Finnish Regulatory Agency Approval for Phase I Study of KAND145	23.10.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Kancera AB

Aktien

A2QQQ4

SE0015658570

KAN

Andere Sprachen

Filter